Trial Profile
A Phase I Study of Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Patients With Logically Advanced Inoperable or Metastatic HER2-Positive Breast Cancer Who Have Received Prior Trastuzumab Based Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Pharmacokinetics
- Sponsors Roche
- 30 Oct 2020 Results published in the Medicine
- 24 Oct 2018 Status changed from active, no longer recruiting to completed.
- 21 Jun 2018 Planned End Date changed from 19 Sep 2019 to 19 Sep 2018.